

826,779
BIOSES &
CAS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:
sssptau182das
LOGINID:
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 09 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BICIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 03 CANCERLIT reload
NEWS 17 Aug 03 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 03 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:53:53 ON 10 SEP 2002

=> file biosis
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 13:54:13 ON 10 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 4 September 2002 (20020904/ED)

=> pdx(W)1
PDX(W)1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s pdx(W)1
328 PDX
2769592 1
L1 214 PDX(W)1

=> s idx(W)1
157 IDX
2769592 1
L2 38 IDX(W)1

=> s ipf(W)1
665 IPF
7 IPFS
669 IPF
(IPF OR IPFS)
2769592 1
L3 64 IPF(W)1

=> s stf(W)1
254 STF
24 STFS
268 STF
(STF OR STFS)
2769592 1
L4 45 STF(W)1

=> s pdx1
L5 81 PDX1

=> s idx1
L6 5 IDX1

=> s ipf1
L7 50 IPF1

=> s stf1
L8 13 STF1

=> s islet(W)duodenum(W)homeo?(W)protein(W)1

```

19580 ISLET
14865 ISLETS
27897 ISLET
      (ISLET OR ISLETS)
16771 DUODENUM
      40 DUODENUMS
      116 DUODENA
16849 DUODENUM
      (DUODENUM OR DUODENUMS OR DUODENA)
994369 HOMEQ?
1234078 PROTEIN
464105 PROTEINS
1423261 PROTEIN
      (PROTEIN OR PROTEINS)
2769592 1
L9      0 ISLET(W) DUODENUM(W) HOMEQ?(W) PROTEIN(W) 1

=> s insulin(W)promoter(W)factor(W)1
      196120 INSULIN
      991 INSULINS
      196290 INSULIN
      (INSULIN OR INSULINS)
      93569 PROMOTER
      23024 PROMOTERS
      102945 PROMOTER
      (PROMOTER OR PROMOTERS)
      666185 FACTOR
      498806 FACTORS
      1051474 FACTOR
      (FACTOR OR FACTORS)
2769592 1
L10     81 INSULIN(W) PROMOTER(W) FACTOR(W) 1

=> s somatostatin(W)transcrip?(W)factor(W)1
      24819 SOMATOSTATIN
      95 SOMATOSTATINS
      24839 SOMATOSTATIN
      (SOMATOSTATIN OR SOMATOSTATINS)
      273003 TRANSCRIP?
      666185 FACTOR
      498806 FACTORS
      1051474 FACTOR
      (FACTOR OR FACTORS)
2769592 1
L11     9 SOMATOSTATIN(W) TRANSCRIP?(W) FACTOR(W) 1

=> s 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 110 or 111
L12     454 L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11

=> s pancrea?
6 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s pancrea?
L13     176946 PANCREA?

=> s duct
=> s duct?
L14     63670 DUCT?

=> s divid
=> s divid? or division or propagat? or proliferat? or mitotic? or mitosis

```

111857 DIVID?
 45962 DIVISION
 9119 DIVISIONS
 52158 DIVISION
 (DIVISION OR DIVISIONS)
 34208 PROPAGAT?
 215599 PROLIFERAT?
 34186 MITOTIC?
 23295 MITOSIS
 3790 MITOSES
 26106 MITOSIS
 (MITOSIS OR MITOSES)
 L15 434631 DIVID? OR DIVISION OR PROPAGAT? OR PROLIFERAT? OR MITOTIC? OR
 MITOSIS

=> s 112 and 113 and 114 and 115
 L16 16 L12 AND L13 AND L14 AND L15

=> save temp
 ENTER L#, L# RANGE, ALL, OR (END):116
 ENTER NAME OR (END):idx1/a
 ANSWER SET L16 HAS BEEN SAVED AS 'IDX1/A'

=> file ca	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	18.26	18.47

FILE 'CA' ENTERED AT 14:07:32 ON 10 SEP 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2002 VOL 137 ISS 11
 FILE LAST UPDATED: 5 Sep 2002 (20020905/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s 116
 695 PDX
 7055386 1
 157 PDX(W)1
 117 IDX
 7055386 1
 35 IDX(W)1
 351 IPF
 11 IPFS

356 IPF
 (IPF OR IPFS)
 7055386 1
 58 IPF(W)1
 350 STF
 41 STFS
 375 STF
 (STF OR STFS)
 7055386 1
 46 STF(W)1
 149 PDX1
 19 IDX1
 30 IPF1
 34 STF1
 20070 ISLET
 11986 ISLETS
 22753 ISLET
 (ISLET OR ISLETS)
 15382 DUODENUM
 48 DUODENUMS
 98 DUODENA
 15431 DUODENUM
 (DUODENUM OR DUODENUMS OR DUODENA)
 34769 HCMEOP
 1397970 PROTEIN
 925628 PROTEINS
 1612137 PROTEIN
 (PROTEIN OR PROTEINS)
 7055386 1
 0 ISLET(W) DUODENUM(W) HCMEOP(W) PROTEIN(W) 1
 139323 INSULIN
 5107 INSULINS
 139917 INSULIN
 (INSULIN OR INSULINS)
 121439 PROMOTER
 42121 PROMOTERS
 138090 PROMOTER
 (PROMOTER OR PROMOTERS)
 710782 FACTOR
 616573 FACTORS
 1122846 FACTOR
 (FACTOR OR FACTORS)
 7055386 1
 82 INSULIN(W) PROMOTER(W) FACTOR(W) 1
 16148 SOMATOSTATIN
 129 SOMATOSTATINS
 16154 SOMATOSTATIN
 (SOMATOSTATIN OR SOMATOSTATINS)
 267101 TRANSCRIPT
 710782 FACTOR
 616573 FACTORS
 1122846 FACTOR
 (FACTOR OR FACTORS)
 7055386 1
 8 SOMATOSTATIN(W) TRANSCRIPT(W) FACTOR(W) 1
 94837 PANCREAS
 94883 DUCT?
 140207 DIVID?
 55853 DIVISION
 5289 DIVISIONS
 59464 DIVISION
 (DIVISION OR DIVISIONS)
 123110 PROPAGAT?
 154870 PROLIFERAT?

23240 MITOTIC?
24306 MITOSIS
1922 MITOSES
25365 MITOSIS
(MITOSIS OR MITOSES)

L17 16 L12 AND L13 AND L14 AND L15

=> duplicate rem

ENTER L# LIST OR (END):116-117

DUPLICATE PREFERENCE IS 'BIOSIS, CA'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

51.53

70.00

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 14:08:13 ON 10 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CA' ENTERED AT 14:08:13 ON 10 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

PROCESSING COMPLETED FOR L16

PROCESSING COMPLETED FOR L17

L18 21 DUPLICATE REM L16-L17 (11 DUPLICATES REMOVED)

=> d l18 1-21 bib ab

L18 ANSWER 1 OF 21 CA COPYRIGHT 2002 ACS

AN 135:131238 CA

TI Bile **duct** progenitor cells and methods of use

IN Pang, Kevin; Homa, Monica

PA USA

SO U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 973,938.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002012653	A1	20020131	US 1997-994539	19971219
	WO 9640872	A1	19961219	WO 1996-US9656	19960607
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	WO 1996-US9656	W	19960607		
	US 1998-973938	A2	19980821		
	US 1995-478064	A	19950607		
AB	The present invention relates to a substantially pure population of viable bile duct progenitor cells, and methods for isolating such cells. The present invention further concerns certain therapeutic uses for such progenitor cells, and their progeny.				

L18 ANSWER 2 OF 21 CA COPYRIGHT 2002 ACS

AN 135:24733 CA

TI **Pancreatic** stem cells and their use in transplantation

IN Abraham, Elizabeth J.; Faustman, Denise; Habener, Joel L.; Vallejo, Mario; Zilewski, Hendrik

PA General Hospital Corporation, USA

SO ECT Int. Appl., 102 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE

PI WO 2001039784 A1 20010607 WO 2000-US33031 20001206
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LK, LF, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
 ZW, AM, AZ, BY, KG, KE, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, ML, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 2001024824 A1 20010927 US 2000-731255 20001206
 US 2001046489 A1 20011129 US 2000-731261 20001206
 PRAI US 1999-169082P P 19991206
 US 2000-215109P P 20000628
 US 2000-238880P P 20001006

AB Methods and compns. are described for the treatment of type I
 insulin-dependent diabetes mellitus and other conditions in a patient
 using newly identified stem cells that are capable of differentiation into
 a variety of **pancreatic** islet cells, including insulin-producing
 beta cells, as well as hepatocytes. Addnl., the patient may be treated
 with an immunosuppressant agent. Nestin has been identified as a mol.
 marker for **pancreatic** stem cells, while cytokeratin-19 serves as
 a marker for a distinct class of islet **ductal** cells. Methods
 are described whereby nestin-pos. stem cells can be isolated from
pancreatic islets and cultured to obtain further stem cells or
 pseudo-islet like structures. Methods for ex vivo differentiation of the
pancreatic stem cells are disclosed. Methods are described
 whereby **pancreatic** stem cells can be isolated, expanded, and
 transplanted into a patient in need thereof, either allogeneically,
 isogeneically or xenogeneically, to provide replacement for lost or damaged
 insulin-secreting cells or other cells. For example, a 3-fold stimulation
 of nestin mRNA levels in the islets cultured in high glucose compared to
 the islets cultured in normal glucose was obsd. Similarly, injection of
 glucagon-like peptide 1 (GLP-1) into mice was found to increase islet mass
 by 2-fold in 48 h.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
 1

AN 2002:280266 BIOSIS
 DN PREV200200280266

TI **Pancreatic** duodenal homeobox-1, **PDX-1**, a
 major regulator of beta cell identity and function.

AU McKinnon, C. M.; Docherty, K. (1)

CS (1) Department of Molecular and Cell Biology, Institute of Medical
 Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD:
 k.docherty@aberddeen.ac.uk UK

SO Diabetologia, (October, 2001) Vol. 44, No. 10, pp. 1203-1214. print.
 ISSN: 0012-186X.

DT General Review

LA English

AB **Pancreatic** duodenal homeobox -1 is a transcription factor that
 is expressed in beta and delta cells of the islets of Langerhans and in
 dispersed endocrine cells of the duodenum. It is involved in regulating
 the expression of a number of key beta-cell genes as well as somatostatin.
 It also plays a pivotal part in the development of the **pancreas**
 and islet cell ontogeny. Thus homozygous disruption of the gene in mice
 and humans results in **pancreatic** agenesis. Heterozygous
 mutations in the gene result in impaired glucose tolerance and symptoms of
 diabetes as seen in MODY4 and late-onset Type II (non-insulin-dependent)
 diabetes mellitus. In adults **pancreatic** duodenal homeobox-1
 expression is increased in **duct** cells of the **pancreas**

that have been induced to **proliferate** and differentiate to form new islets. Defects in **pancreatic** duodenal homeobox-1 could therefore contribute to Type II diabetes by affecting compensatory mechanisms that increase the rate of beta-cell neogenesis to meet the increased insulin secretory demand. It could also be a pharmacological target for beta-cell defects in Type II diabetes, while its role as a regulator of islet stem cell activity is being exploited to produce a replenishable source of islet tissue for transplantation in Type I (insulin-dependent) diabetes mellitus.

L18 ANSWER 4 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
2

AN 2001:142229 BIOSIS

DN PREV200100142229

TI PDX:PBX complexes are required for normal **proliferation** of **pancreatic** cells during development.

AU Dutta, Sanjoy; Gannon, Maureen; Peers, Bernard; Wright, Chris; Bonner-Weir, Susan; Montminy, Marc (1)

CS (1) Clayton Laboratories for Peptide Biology, Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA, 92037; montminy@salk.edu USA

SO Proceedings of the National Academy of Sciences of the United States of America, (January 30, 2001) Vol. 98, No. 3, pp. 1065-1070. print.
ISSN: 0027-8424.

DT Article

LA English

SL English

AB The homeobox factor **PDX-1** is a key regulator of **pancreatic** morphogenesis and glucose homeostasis; targeted disruption of the **PDX-1** gene leads to **pancreatic** agenesis in **pdx-1**(-/-) homozygotes. **Pdx-1** heterozygotes develop normally, but they display glucose intolerance in adulthood. Like certain other homeobox proteins, **PDX-1** contains a consensus FPWMK motif that promotes heterodimer formation with the ubiquitous homeodomain protein PBX. To evaluate the importance of **PDX-1**:PBX complexes in **pancreatic** morphogenesis and glucose homeostasis, we expressed either wild-type or PBX interaction defective **PDX-1** transgenes under control of the **PDX-1** promoter. Both wild-type and mutant **PDX-1** transgenes corrected glucose intolerance in **pdx-1** heterozygotes. The wild-type **PDX-1** transgene rescued the development of all **pancreatic** lineages in **pdx-1**(-/-) animals, and these mice survived to adulthood. In contrast, **pancreata** from **pdx-1**(-/-) mice expressing the mutant **PDX-1** transgene were hypoplastic, and these mice died within 3 weeks of birth from **pancreatic** insufficiency. All **pancreatic** cell types were observed in **pdx-1**(-/-) mice expressing the mutant **PDX-1** transgene; but the islets were smaller, and increased numbers of islet hormone-positive cells were noted within the **ductal** epithelium. These results indicate that **PDX-1**:PBX complexes are dispensable for glucose homeostasis and for differentiation of stem cells into **ductal**, endocrine, and acinar lineages; but they are essential for expansion of these populations during development.

L18 ANSWER 5 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
3

AN 2001:214765 BIOSIS

DN PREV200100314765

TI Multipotential nestin-positive stem cells isolated from adult **pancreatic** islets differentiate ex vivo into **pancreatic** endocrine, exocrine, and hepatic phenotypes

AU Zulewski, Henryk; Abraham, Elizabeth J.; Gerlach, Melissa J.; Daniel, Philip B.; Moritz, Wolfgang; Muller, Beat; Vallejo, Mario; Thomas, Melissa

K.; Habener, Joel F. (1)
 CS (1) Laboratory of Molecular Endocrinology, Massachusetts General Hospital,
 55 Fruit St., WEL320, Boston, MA, 02114: jhabener@partners.org USA
 SO Diabetes, (March, 2001) Vol. 50, No. 3, pp. 521-533. print.
 ISSN: 0012-1797.
 DT Article
 LA English
 SL English
 AB The endocrine cells of the rat **pancreatic** islets of Langerhans,
 including insulin-producing beta-cells, turn over every 40-50 days by
 processes of apoptosis and the **proliferation** and differentiation
 of new islet cells (neo-genesis) from progenitor epithelial cells located
 in the **pancreatic ducts**. However, the administration
 to rats of islet trophic factors such as glucose or glucagon-like peptide
 1 for 48 h results in a doubling of islet cell mass, suggesting that islet
 progenitor cells may reside within the islets themselves. Here we show
 that rat and human **pancreatic** islets contain a heretofore
 unrecognized distinct population of cells that express the neural stem
 cell-specific marker nestin. Nestin-positive cells within
pancreatic islets express neither the hormones insulin, glucagon,
 somatostatin, or **pancreatic** polypeptide nor the markers of
 vascular endothelium or neurons, such as collagen IV and galanin. Focal
 regions of nestin-positive cells are also identified in large, small, and
 centrolobular **ducts** of the rat **pancreas**.
 Nestin-positive cells in the islets and in **pancreatic**
ducts are distinct from **ductal** epithelium because they
 do not express the **ductal** marker cytokeratin 19 (CK19). After
 their isolation, these nestin-positive cells have an unusually extended
proliferative capacity when cultured in vitro (apprx8 months), can
 be cloned repeatedly, and appear to be multipotential. Upon confluence,
 they are able to differentiate into cells that express liver and exocrine
pancreas markers, such as alpha-fetoprotein and **pancreatic**
 amylase, and display a **ductal**/endocrine phenotype with
 expression of CK19, neural-specific cell adhesion molecule, insulin,
 glucagon, and the **pancreas**/duodenum specific homeodomain
 transcription factor, **IDX-1**. We propose that these
 nestin-positive islet-derived progenitor (NIP) cells are a distinct
 population of cells that reside within **pancreatic** islets and may
 participate in the neogenesis of islet endocrine cells. The NIP cells that
 also reside in the **pancreatic ducts** may be
 contributors to the established location of islet progenitor cells. The
 identification of NIP cells within the **pancreatic** islets
 themselves suggest possibilities for treatment of diabetes, whereby NIP
 cells isolated from **pancreas** biopsies could be expanded ex vivo
 and transplanted into the donor/recipient.

L18 ANSWER 6 OF 21 CA COPYRIGHT 2002 ACS

AN 133:38709 CA

TI An animal model for identifying a common stem/progenitor to liver cells
 and **pancreatic** cells

IN Sarvetnick, Nora; Krakowski, Michelle L.; Kritzik, Marcie R.

PA The Scripps Research Institute, USA

SO PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DT Patent

LA English

PAN. CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000036091	A2	20000622	WO 1999-US29490	19991213
	WO 2000036091	A3	20001109		

W: AE, AL, AM, AT, AU, AZ, BA, BE, BG, BF, BY, CA, CH, CN, CR, CU,
 CZ, DE, DK, DM, EE, ES, FI, GR, GD, GE, GH, GM, HR, HU, ID, IL,
 IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
 SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1141247 A2 20011010 EP 1999-967280 19991213
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

US 2001013134 A1 20010809 US 2001-826779 20010405
 PRAI US 1998-212531 A2 19981216 parent of infant
 WO 1999-US29490 W 19991213

AB The invention provides animal models, where the ectopic expression of KGF, EGF, or both is under the control of a **pancreas**-specific promoter, e.g., the insulin promoter. The expression of KGF in the ins-KGF **pancreatic** islets of Langerhans results in enlarged islets, with substantial **proliferation** of **duct** cells within the islet mass, and the presence of albumin and alpha-fetoprotein-producing hepatocytes in the islets of the ins-KGF **pancreata**. The comps. and methods disclosed are useful for identifying and isolating **pancreatic** stem/progenitor cells, including a common stem/progenitor to liver cells and **pancreatic** cells.

L18 ANSWER 7 OF 21 CA COPYRIGHT 2002 ACS

AN 135:301720 CA

TI Human **pancreatic** stem cell and diabetes cell therapy

AU Pattou, Francois; Kerr-Conte, Julie; Gmyr, Valery; Vandewalle, Brigitte; Vantyghem, Marie-Christine; Lecomte-Houcke, Martine; Proye, Charles; Lefebvre, Jean

CS Hcspitalio-Universitaire, UFRES 1048 de Universite de Lille 2 et Service de Chirurgie Generale et Endocrinienne, Centre Hospitalier, Universitaire de Lille, Lille, F59037, Fr.

SO Bulletin de l'Academie Nationale de Medecine (Paris, France) (2000), 184(9), 1887-1901

CODEN: BANMAC; ISSN: 0001-4079

PB Academie Nationale de Medecine

DT Journal; General Review

LA French

AB A review, with refs. Cell therapy offers today important perspectives for the treatment of type 1 diabetes. The current utilization of primary human islets of Langerhans nevertheless forbids all hope of developing this treatment on a large scale. The recent description of the persistence of stem cells capable of **proliferating** and differentiating in the adult **pancreas** offers an attractive alternative for the prodn. in vitro of homologous insulin-secreting cells. We first reproduced in vitro from human islet preps. the **proliferation** of **ductal** epithelial structures and their progressive organization. Thereafter, we focused on the description of a reproducible source of human **ductal** cells by the transdifferentiation of exocrine preps. More recently we described in these exocrine derived **ductal** cells the expression the of **insulin promoter factor-1** (**IPF-1**/otherwise known as **PDX-1**), a transcription factor essential for the differentiation of **ductal** cells into endocrine cells during both development and **pancreatic** regeneration. If the **proliferation** and differentiation of these cells is confirmed, this approach could lead to the description of an abundant source of human **pancreatic** stem cells for the prodn. ex vivo of human insulin secreting cells and may even allow autologous cell therapy, in the absence of immunosuppression.

RELCNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
4

AN 2001:267534 BIOSIS

DN PREV200100267534

TI Adult human cytokeratin 19-positive cells reexpress **insulin promoter factor 1** in vitro: Further evidence for pluripotent **pancreatic** stem cells in humans.

AU Gmyr, Valery; Kerr-Conte, Julie (1); Belaich, Sandrine; Vandewalle, Brigitte; Leteurtre, Emmanuelle; Vantyghem, Marie Christine; Lecomte-Houcke, Martine; Proye, Charles; Lefebvre, Jean; Pattou, Francois
CS (1) Laboratory of Cell Culture, University Hospital Center of Lille, 1 Place de Verdun, Lille, 59045: jkerr-conte@univ-lille2.fr France
SO Diabetes, (October, 2000) Vol. 49, No. 10, pp. 1671-1680. print.
ISSN: 0012-1797.

DT Article

LA English

SL English

AB Human **pancreatic** cells with a typical **ductal** phenotype and potential to **proliferate** can be obtained in vitro, but the differentiation capacity of these putative human **pancreatic** stem cells remains to be documented. We investigated the protein and mRNA expression of **insulin promoter factor 1 (IPF-1)** (or **pancreas/duodenal homeobox 1**), a transcription factor critical for **pancreatic** development and endocrine cell neogenesis, in human **pancreatic ductal** cells derived from cultured exocrine tissue. In vitro, exocrine cells rapidly adhered (within 12 h) and were de-/transdifferentiated to **ductal** cells after 3 days with a dramatic loss of amylase protein ($n = 4$, $92 \pm 3.3\%$, $P < 0.05$ vs. day 1) and a simultaneous increase of **ductal** cytokeratin 19 protein ($n = 4$, 3.4-fold on day 3 and 7-fold on day 9, $P < 0.05$ vs. day 1). **IPF-1** protein and mRNA levels were low to undetectable in exocrine preparations before culture. After 2 days of culture, a 3.2-fold increase in **IPF-1** protein was observed, corresponding to the characteristic 46-kDa protein in Western blots. Reverse transcriptase-polymerase chain reaction confirmed a 10.5-fold increase in **IPF-1** mRNA levels after 3 days of culture ($n = 5$, $P < 0.001$ vs. day 1). Double immunocytochemistry showed direct evidence that **IPF-1** appeared during culture in these exocrine-derived **ductal** cells (cytokeratin 7-positive) and was not merely in contaminating endocrine cells (chromogranin A-positive). In conclusion, we describe herein the first converging evidence on both the molecular and protein level that human cells with a typical **ductal** phenotype derived ex vivo from **pancreatic** exocrine tissue (obtained from healthy donors) can reexpress **IPF-1** in culture, suggesting their **pancreatic** precursor/stem cell potential.

L18 ANSWER 9 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
5

AN 2000:377198 BIOSIS

DN PREV200000377198

TI Modulation of rat **pancreatic** acinoductal transdifferentiation and expression of **PDX-1** in vitro.

AU Rooman, I.; Heremans, Y.; Heimberg, H.; Bouwens, L. (1)
CS (1) Department of Experimental Pathology, VUB, Laarbeeklaan 103, B-1090, Brussels Belgium

SO Diabetologia, (July, 2000) Vol. 43, No. 7, pp. 907-914. print.
ISSN: 0012-186X.

DT Article

LA English

SL English

AB Aims/hypothesis: In adult **pancreatic** regeneration models exocrine acini are found to transdifferentiate to **duct**-like

complexes. This has also been associated with the formation of new endocrine islet cells. We aimed to establish an in vitro model in which this transdifferentiation process is characterised and can be modulated. Methods: Purified rat **pancreatic** acini were cultured in suspension. Differentiation was analysed by immunocytochemistry, electron microscopy, western blotting and RT-PCR. Results: During culture acinar cells directly transdifferentiated without **dividing**, the cells lost their acinar phenotype and started to express cytokeratins 20 and 7 and fetal liver kinase-1 (Flk-1) receptors for vascular endothelial growth factor. Expression of the acinar **pancreatic** exocrine transcription factor (PTF-1) remained and the **pancreatic** duodenal homeobox-containing transcription factor (**PDX-1**) was induced. When transdifferentiation was completed, the cells started to express protein gene product 9.5, a panneuroendocrine marker. By combining these features, the transdifferentiated cells show similar characteristics to precursor cells during active beta-cell neogenesis. We were able to modulate the differentiation state by addition of nicotinamide or sodium butyrate, agents which are known to stimulate endocrine differentiation in other models. Conclusion/interpretation: Here, we present an in vitro system in which the cellular differentiation of putative **pancreatic** endocrine precursor cells and their **PDX-1** expression can be modulated, thereby providing a possible model for the study of beta-cell transdifferentiation.

L18 ANSWER 10 OF 21 CA COPYRIGHT 2002 ACS

AN 133:84532 CA

TI Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein **IDX-1** and increase islet size in mouse **pancreas**

AU Stoffers, Doris A.; Kieffer, Timothy J.; Hussain, Mehboob A.; Drucker, Daniel J.; Bonner-Weir, Susan; Habener, Joel F.; Egan, Josephine M.

CS Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

SO Diabetes (2000), 49(5), 741-748

CODEN: DIAEAB; ISSN: 0012-1797

PB American Diabetes Association

DT Journal

LA English

AB Diabetes is caused by a failure of the **pancreas** to produce insulin in amounts sufficient to meet the body's needs. A hallmark of diabetes is an abs. (type 1) or relative (type 2) redn. in the mass of **pancreatic** .beta.-cells that produce insulin. Mature .beta.-cells have a life-span of .apprx.48-56 days (rat) and are replaced by the replication of preexisting .beta.-cells and by the differentiation and **proliferation** of new .beta.-cells (neogenesis) derived from the **pancreatic ducts**. The insulinotropic hormone glucagon-like peptide (GLP)-1, which is produced by the intestine, enhances the **pancreatic** expression of the homeodomain transcription factor **IDX-1** that is crit. for **pancreas** development and the transcriptional regulation of the insulin gene. Concomitantly, GLP-1 administered to diabetic mice stimulates insulin secretion and effectively lowers their blood sugar levels. GLP-1 also enhances .beta.-cell neogenesis and islet size. Thus, in addn. to stimulating insulin secretion, GLP-1 stimulates the expression of the transcription factor **IDX-1** while stimulating .beta.-cell neogenesis and may thereby be an effective treatment for diabetes.

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:38563 BIOSIS

DN PREV200100038563

TI Hydrolysed casein diet protects BB rats from developing diabetes by

promoting islet neogenesis.

AU Wang, Gen-Sheng; Gruber, Heidi; Smyth, Peter; Pulido, Olga; Rosenberg, Lawrence; Duguid, William; Scott, Fraser W. (1)

CS (1) Laboratory N1, Ottawa Hospital Research Institute, Ottawa Hospital-General Campus, 501 Smyth Road, Ottawa, ON, K1H 8L6: fscott@ottawahospital.on.ca Canada

SO Journal of Autoimmunity, (Dec., 2000) Vol. 15, No. 4, pp. 407-416. print. ISSN: 0896-8411.

DT Article

LA English

SL English

AB Feeding diabetes-prone BioBreeding (BBdp) rats a hydrolysed-casein (HC)-based semi-purified diet results in two-to-three-fold fewer diabetes cases compared with feeding cereal-based diets such as NIH-07 (NIH). We showed previously that young NIH-fed BBdp rats had decreased islet area at a time when classic insulinitis was minimal. Rats fed an HC diet maintained near normal islet area followed 3-4 weeks later by a deviation of the **pancreas** cytokine pattern from Th1 to Th2/Th3. This finding raised the possibility that BBdp rats were more susceptible to diet-induced changes in islet homeostasis. To investigate this possibility further, BBdp rats were fed an NIH or HC diet from days 23 to 45. Bouin's fixed sections of **pancreas** were stained with H & E or antibodies for insulin and glucagon. Cell **proliferation** nuclear antigen (PCNA) was used as a marker of cell **proliferation** and cells were stained for putative markers of islet neogenesis, cytokeratin 20 (CK20) and Bcl-2. Apoptotic bodies were recognized by morphological features and by TUNEL-positive staining. BBdp rats fed an HC diet had a significantly higher beta-cell fraction than rats fed NIH, whereas alpha-cell fraction and beta-cell size were not affected by diet or rat type. Apoptotic bodies of beta-cells were rare and unaffected by diet. The number of PCNA+ beta-cells was not affected by diet. CK20 expression was localized in the **ductular** system and at the periphery of islets in rats aged 7 and 45 days. There were more CK20+ islets in BBdp rats fed NIH than in those fed HC but the CK20 area fraction was unaffected by diet. Bcl-2 expression was scattered among **ducts** and central acinar cells. The number of extra-islet insulin+ and glucagon+ clusters (<four cells) was significantly higher in animals fed the HC diet compared with those fed NIH. Most of the insulin+ clusters were also homeobox-containing transcription factor **pancreas** duodenum homeobox gene-1 (**PDX-1**) positive. Glucagon+/PDX-1+ clusters were rarely found. These data are consistent with a shift in **pancreas** homeostasis that maintains islet cell mass by increased islet neogenesis, a process that was enhanced in animals fed a diabetes-retardant diet.

L18 ANSWER 12 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE 6

AN 2000:216835 BIOSIS

DN PREV200000216835

TI Diabetes and **pancreatic** tumours in transgenic mice expressing Pa X 6.

AU Yamaoka, T. (1); Yano, M.; Yamada, T.; Matsushita, T.; Moritani, M.; Ii, S.; Yoshimoto, K.; Hata, J.; Itakura, M.

CS (1) Otsuka Department of Molecular Nutrition, School of Medicine, University of Tokushima, Tokushima, 770-8503 Japan

SO Diabetologia, (March, 2000) Vol. 43, No. 3, pp. 332-339. ISSN: 0012-186X.

DT Article

LA English

SL English

AB Aims/hypothesis: Both endocrine and exocrine cells of the **pancreas** differentiate from epithelial cells of primitive **pancreatic ducts**, and four types of **pancreatic** islet cells (alpha, beta, delta, and FP cells) are derived from the common pluripotent

precursor cells. Although Pa X 6 is expressed in all islet cells, Pa X 4 is detected only in beta cells. In homozygous Pa X 4-null mice, beta cells are absent, whereas the number of alpha cells is increased. Therefore, we hypothesized that the balance of Pa X 4 and 6 is one of the determinants by which the common progenitor cells differentiate into alpha or beta cells. Methods: To change this balance, we generated transgenic mice overexpressing Pa X 6 driven by the insulin promoter or the **PDX1** promoter. Results: In both types of transgenic mice, normal development of beta cells was disturbed, resulting in apoptosis of beta cells and diabetes. In Insulin/Pa X 6-Tg mice, beta cells were specifically affected, whereas in PDX/Pa X 6-Tg mice, developmental abnormalities involved the whole **pancreas** including hypoplasia of the exocrine **pancreas**. Furthermore, PDX/Pa X 6-Tg mice experienced **proliferation** of both **ductal** epithelia and islet cells and subsequent cystic adenoma of the **pancreas**. Conclusion/interpretation: These findings suggest that Pa X 6 promotes the growth of **ductal** epithelia and endocrine progenitor cells and that the suppression of Pa X 6 is necessary for the normal development of beta cells and the exocrine **pancreas**.

L18 ANSWER 13 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 2000:59802 BIOSIS

DN PREV2000000059802
TI Expansion of **Pdx1**-expressing **pancreatic** epithelium and

islet neogenesis in transgenic mice overexpressing transforming growth factor alpha.

AU Song, Si Young; Gannon, Maureen; Washington, M. K.; Scoggins, Charles R.; Meszoely, Ingrid M.; Goldenring, James R.; Marino, Christopher R.; Sandgren, Eric P.; Coffey, Robert J., Jr.; Wright, Christopher V. E.; Leach, Steven D. (1)

CS (1) Division of Surgical Oncology, T-2104 Medical Center North, Vanderbilt University Medical Center, 21st and Garland Streets, Nashville, TN USA

SO Gastroenterology, (Dec., 1999) Vol. 117, No. 5, pp. 1416-1426.
ISSN: 0016-5085.

DT Article

LA English

SL English

AB Background & Aims: The progenitor cells responsible for transforming growth factor (TGF)-alpha-induced **pancreatic ductal** metaplasia and neoplasia remain uncharacterized. During **pancreatic** development, differentiated cell types arise from **ductal** progenitor cells expressing the **Pdx1** homeodomain transcription factor. The aims of this study were, first, to evaluate the role of **Pdx1**-expressing stem cells in MT-TGFalpha transgenic mice, and second, to further characterize cell **proliferation** and differentiation in this model. Methods: To assess **Pdx1** gene expression in normal and metaplastic epithelium, we performed in vivo reporter gene analysis using heterozygous **Pdx1lacZ/+** and bigenic **Pdx1lacZ/+**/MT-TGFalpha mice. Results: **Pdx1lacZ/+**/MT-TGFalpha bigenics showed up-regulated **Pdx1** expression in premalignant metaplastic **ductal** epithelium. In addition to **Pdx1** gene activation, TGF-alpha-induced metaplastic epithelium demonstrated a pluripotent differentiation capacity, as evidenced by focal expression of Pax6 and initiation of islet cell neogenesis. The majority of **Pdx1**-positive epithelial cells showed no expression of insulin, similar to the pattern observed during embryonic development. Conclusions: Overexpression of TGF-alpha induces expansion of a **Pdx1**-expressing epithelium characterized by focal expression of Pax6 and initiation of islet neogenesis. These findings suggest that premalignant events induced by TGF-alpha in mouse **pancreas** may recapitulate a developmental program active during embryogenesis.

L18 ANSWER 14 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
AN 1999:324535 BIOSIS

DN PREV199900324535
 TI Activation of the **Pdx1** homeobox gene during TGF α -induced premalignant **pancreatic ductal proliferation**
 : In vivo reporter gene analysis using "double transgenic" mice.
 AU Song, Si Young (1); Gannon, Maureen (1); Meszoely, Ingrid M. (1); Scoggins, Charles R. (1); Yang, LiYing (1); Wright, Christopher V. E. (1); Coffey, Robert J. (1); Leach, S. D.
 CS (1) Vanderbilt Univ Med Ctr, Nashville, TN USA
 SO Gastroenterology, (April, 1999) Vol. 116, No. 4 PART 2, pp. A1164.
 Meeting Info.: Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association Orlando, Florida, USA May 16-19, 1999 American Gastroenterological Association
 . ISSN: 0016-5085.
 DT Conference
 LA English

L18 ANSWER 15 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1999:293778 BIOSIS

DN PREV199900293778

TI Sustained **proliferation** of **PDX-1**+ cells derived from human islets.

AU Beattie, Gillian M.; Itkin-Ansari, Pamela; Cirulli, Vincenzo; Leibowitz, Gil; Lopez, Ana D.; Bossie, Stuart; Mally, Martin I.; Levine, Fred; Hayek, Alberto (1)

CS (1) Islet Research Laboratory, Department of Pediatrics, UCSD, 9894 Genesee Ave., La Jolla, CA, 92037 USA

SO Diabetes, (May, 1999) Vol. 48, No. 5, pp. 1013-1019.
 ISSN: 0012-1797.

DT Article

LA English

SL English

AB Ex vivo expansion of human beta-cells is an important step toward the development of cell-based insulin delivery systems in type 1 diabetes. Here, we report that human **pancreatic** endocrine cells can be expanded through 15 cell doublings in vitro for an estimated total 30,000-fold increase in cell number. We believe that the cells resulting from these cultures are of beta-cell origin, since they uniformly express the transcription factor **PDX-1** (**STF-1**, **IDX-1**, **IPF-1**), which is initially seen only in cells positive for insulin and negative for the ductal cell marker cytokeratin (CK)-19. To rule out the possibility that **PDX-1** expression might be induced by the culture conditions used here, cells from isolated human **pancreatic ducts** were cultured under the same conditions as the islet cells. Cells in these cultures expressed CK-19 but not **PDX-1**. Although the expanded beta-cells continued to express **PDX-1**, insulin expression was lost over time. Whether reexpression of islet-specific genes in vitro is essential for successful cell transplantation remains to be determined.

L18 ANSWER 16 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
 7

AN 2000:95419 BIOSIS

DN PREV200000095419

TI **PDX-1** and Msx-2 expression in the regenerating and developing **pancreas**

AU Krut'nik, M. R.; Jones, E.; Chen, Z.; Krakowski, M.; Krahf, T.; Good, A.; Wright, C.; Fox, H.; Sarvetnick, N. (1)

CS (1) Department of Immunology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037 USA

SO Journal of Endocrinology, (Dec., 1999) Vol. 163, No. 3, pp. 523-530.
 ISSN: 0022-0795

ET Article

LA English

SL English

AB We have observed **pancreatic duct** cell

proliferation and islet regeneration in transgenic mice whose **pancreata** produce interferon gamma (IFNg mice). We have previously demonstrated that new islet cells derive from endocrine progenitor cells in the **pancreatic ducts** of this model. The current study was initiated to define these endocrine progenitor cells further and to identify novel markers associated with **pancreatic** regeneration. Importantly, we have found that **PDX-1**, a transcription factor required for insulin gene transcription as well as for **pancreatic** development during embryogenesis, is expressed in the **duct** cells of IFNg mice. This striking observation suggests an important role for **PDX-1** in the marked regeneration observed in IFNg mice, paralleling its critical function during ontogeny. Also demonstrated was elevated expression of the homeobox-containing protein **Msx-2** in the **pancreata** of fetal mice as well as in adult IFNg mice, identifying this molecule as a novel marker associated with **pancreatic** development and regeneration as well. The identification of **PDX-1** and **Msx** in the **ducts** of the IFNg transgenic **pancreas** but not in the **ducts** of the non-transgenic **pancreas** suggests that these molecules are associated with endocrine precursor cells in the **ducts** of the IFNg transgenic mouse.

L18 ANSWER 17 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
8

AN 1999:153690 BIOSIS

DN PREV199900153690

TI The homeodomain protein **IDX-1** increases after an early burst of **proliferation** during **pancreatic** regeneration.

AU Sharma, Arun; Zangen, David H.; Reitz, Petra; Taneja, Monica; Lissauer, Matthew E.; Miller, Christopher P.; Weir, Gordon C.; Habener, Joel F.; Bonner-Weir, Susan (1)

CS (1) Joslin Diabetes Cent., One Joslin Pl., Boston, MA 02215 USA

SO Diabetes, (March, 1999) Vol. 48, No. 3, pp. 507-513.

ISSN: 0012-1797.

DT Article

LA English

AB Islet duodenal homeobox 1 (**IDX-1/IPF-**

1/STF-1/PDX-1), a homeodomain protein that transactivates the insulin promoter, has been shown by targeted gene ablation to be required for **pancreatic** development. After 90% **pancreatectomy** (Px), the adult **pancreas** regenerates in a process recapitulating embryonic development, starting with a burst of **proliferation** in the epithelium of the common **pancreatic duct**. In this model, **IDX-1** mRNA was detected by semiquantitative reverse transcription-polymerase chain reaction in total RNA from isolated common **pancreatic ducts** at levels 10% of those of isolated islets. The **IDX-1** mRNA levels were not significantly different for common **pancreatic ducts** of Px, sham Px, and unoperated rats and did not change with time after surgery. By immunoblot analysis, **IDX-1** protein was only faintly detected in these **ducts** 1 and 7 days after Px or sham Px but was easily detected at 2 and 3 days after Px. Similarly, **IDX-1** immunostaining was barely detectable in sham or unoperated **ducts** but was strong in **ducts** at 2-3 days after Px. The increase of **IDX-1** immunostaining followed that of BrdU incorporation (**proliferation**). These results indicate a posttranscriptional regulation of the **IDX-1** expression in **ducts**. In addition, islets isolated 3-7 d after Px showed higher **IDX-1** protein expression than control islets. Thus, in **pancreatic** regeneration **IDX-1** is upregulated in newly divided ductal cells

as well as in islets. The timing of enhanced expression of **IDX-1** implies that **IDX-1** is not important in the initiation of regeneration but may be involved in the differentiation of **ductal** cells to beta-cells.

L18 ANSWER 18 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1999:289195 BIOSIS

DN PREV199900289195

TI Ontogeny of peptide growth factor and transcription factor expression during induced islet cell neogenesis in the neonatal rat **pancreas**

AU Arany, E. (1); Strutt, B.; Duvillie, B.; Hill, D. J.

CS (1) Lawson Research Institute, St Joseph's Health Centre, University of Western Ontario, London, Ontario, N6A 4V2 Canada

SO Journal of Endocrinology, (March, 1999) Vol. 160, No. SUPPL., pp. P124.

Meeting Info.: 18th Joint Meeting of the British Endocrine Societies Bournemouth, England, UK April 12-15, 1999 British Endocrine Societies . ISSN: 0022-0795.

DT Conference

LA English

L18 ANSWER 19 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC. DUPLICATE 9

AN 1997:390039 BIOSIS

DN PREV199799689242

TI Demonstration of two different processes of beta-cell regeneration in a new diabetic mouse model induced by selective perfusion of alloxan.

AU Waguri, Masako (1); Yamamoto, Koji; Miyagawa, Jun-Ichiro; Tochino, Yoshihiro; Yamamori, Katsumi; Kajimoto, Yoshitaka; Nakajima, Hiromu; Watada, Hirotaka; Yoshiuchi, Issei; Itoh, Naoto; Imagawa, Akihisa; Namba, Mitsuyoshi; Kuwajima, Masamichi; Yamasaki, Yoshimitsu; Hanafusa, Toshiaki; Matsuura, Yuji

CS (1) Second Dep. Intern. Med., Osaka Univ. Med. Sch., 2-2 Yamada-oka, Suita, Osaka 565 Japan

SO Diabetes, (1997) Vol. 46, No. 8, pp. 1281-1290. ISSN: 0012-1797.

DT Article

LA English

AB To clarify the regeneration process of **pancreatic** beta-cells, we established a new mouse model of diabetes induced by selective perfusion of alloxan after clamping the superior mesenteric artery. In this model, diabetes could be induced by the destruction of beta-cells in alloxan-perfused segments, while beta-cells in nonperfused segments were spared. Intraperitoneal glucose tolerance tests showed glucose intolerance, which gradually ameliorated and was completely normalized in 1 year with a concomitant increase of insulin content in the **pancreas**. Histological examination showed neo-islet formation in the alloxan-perfused segment and the **proliferation** of spared beta-cells in the nonperfused segment. In the alloxan-perfused segment, despite a marked reduction of islets in size and number at an early stage, both the number of islets, including islet-like cell clusters (ICCs), and the relative islet area significantly increased at a later stage. Increased single beta-cells and ICCs were located in close contact with **duct** cell lining, suggesting that they differentiated from **duct** cells and that such extra-islet precursor cells may be important for beta-cell regeneration in beta-cell-depleted segment. In addition to beta cells, some nonhormone cells in ICCs were positive for nuclear **insulin promoter factor 1**, which indicated that most, if not all, nonhormone cells positive for this factor were beta-cell precursors. In the nonperfused segment, the islet area increased significantly, and the highest 5-bromo-2-deoxyuridine-labeling index in beta-cells was observed at day 5, while the number of islets did not increase significantly. This indicated that the regeneration of islet endocrine cells occurs mostly through the

1999
data

proliferation of preexisting intra-islet beta-cells in the nonperfused segment. In conclusion, the regeneration process of beta-cells varied by circumstance. Our mouse model is useful for studying the mechanism of regeneration, since differentiation and **proliferation** could be analyzed separately in one **pancreas**.

L18 ANSWER 20 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
10

AN 1997:202299 BIOSIS

DN PREV199799501502

TI Alpha-Cell neogenesis in an animal model of IDDM.

AU O'Reilly, Lorraine A.; Gu, Danling; Sarvetnick, Nora; Edlund, Helena; Phillips, Jenny M.; Fulford, Tony; Cooke, Anne (1)

CS (1) Dep. Pathology, Immunology Div., Univ. Cambridge, Tennis Court Road, Cambridge CB2 1QP UK

SO Diabetes, (1997) Vol. 46, No. 4, pp. 599-606.

ISSN: 0012-1797.

DT Article

LA English

AB Currently there is debate regarding the capacity of **pancreatic** islets to regenerate in adult animals. Because **pancreatic** endocrine cells are thought to arise from **duct** cells, we examined the **pancreatic ductal** epithelium of the diabetic NOD mouse for evidence of islet neogenesis. We have evidence of **duct proliferation** as well as **ductal** cell differentiation, as suggested by bromodeoxyuridine-labeling and the presence of glucagon-containing cells within these **ducts**. In addition, the **ductal** epithelia in diabetic NOD mice expressed the neuroendocrine markers neuropeptide Y and tyrosine hydroxylase. These **ducts** also expressed the homeobox gene product, insulin promoter factor 1. **Ductal** cell **proliferation** and expression of these markers was not observed in transgenic NOD mice (NOD-E), which do not develop clinical or histopathological symptoms of IDDM. This suggests that the observed **ductal** cell **proliferation** and differentiation was a direct result of beta-cell destruction and insulin insufficiency in these adult diabetic mice, which further suggests that these events are recapitulating islet ontogeny observed during embryogenesis. It is possible that comparable processes occur in the human diabetic **pancreas**.

L18 ANSWER 21 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
11

AN 1996:216872 BIOSIS

DN PREV199698773001

TI **PDX-1** is required for **pancreatic** outgrowth and differentiation of the rostral duodenum.

AU Offield, Martin F.; Jetton, Tom L.; Labosky, Patricia A.; Ray, Michael; Stein, Roland W.; Magnuson, Mark A.; Hogan, Brigid L.; Wright, Christopher V. E. (1)

CS (1) Dep. Cell Biol., Vanderbilt Univ. Sch. Med., 1161 21st Avenue South, Nashville, TN 37232-2175 USA

SO Development (Cambridge), (1996) Vol. 122, No. 3, pp. 983-995.
ISSN: 0950-1991.

DT Article

LA English

AB It has been proposed that the *Xenopus* homeobox gene, *XlHbox8*, is involved in endodermal differentiation during **pancreatic** and duodenal development (Wright, C. V. E., Schnegelsberg, P. and De Robertis, E. M. (1988). Development 105, 787-794). To test this hypothesis directly, gene targeting was used to make two different null mutations in the mouse *XlHbox8* homolog, *pdx-1*. In the first, the second **pdx-1** exon, including the homeobox, was replaced by a neomycin resistance cassette. In the second, a lacZ reporter was fused in-frame with the N terminus of **PDX-1**, replacing most of the homeodomain.

Neonatal **pdx-1**-mice are apancreatic, in confirmation of previous reports (Jonsson, J., Carlsson, L., Edlund, T. and Edlund, H. (1994). Nature 371, 606-609). However, the **pancreatic** buds do form in homozygous mutants, and the dorsal bud undergoes limited **proliferation** and outgrowth to form a small, irregularly branched, **ductular** tree. This outgrowth does not contain insulin or amylase-positive cells, but glucagon-expressing cells are found. The rostral duodenum shows a local absence of the normal columnar epithelia) lining, villi, and Brunner's glands, which are replaced by a GLUT2-positive cuboidal epithelium resembling the bile **duct** lining. Just distal of the abnormal epithelium, the numbers of enteroendocrine cells in the villi are greatly reduced. The **PDX-1**/beta-galactosidase fusion allele is expressed in **pancreatic** and duodenal cells in the absence of functional **PDX-1**, with expression continuing into perinatal stages with similar boundaries and expression levels. These results offer additional insight into the role of **pdx-1** in the determination and differentiation of the posterior foregut, particularly regarding the **proliferation** and differentiation of the **pancreatic** progenitors.

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

43.33

113.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-2.95

-2.95

STN INTERNATIONAL LOGOFF AT 14:09:00 ON 10 SEP 2002

L Number	Hits	Search Text	DB	Time stamp
1	160	pdx-1 or idx-1 or ipf-1 or stf-1 or pdx1 or idx1 or ipf1 or stf1	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:35
2	388	(424/1.49).CCLS.	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:35
3	198	(424/9.34).CCLS.	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:40
4	3933	(435/4).CCLS.	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:40
5	1656	(435/7.21).CCLS.	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:40
6	1397	(435/7.23).CCLS.	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:40
7	205	(435/960).CCLS.	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:40
8	7012	((424/1.49).CCLS.) or ((424/9.34).CCLS.) or ((435/4).CCLS.) or ((435/7.21).CCLS.) or ((435/7.23).CCLS.) or ((435/960).CCLS.)	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:41
9	9	(pdx-1 or idx-1 or ipf-1 or stf-1 or pdx1 or idx1 or ipf1 or stf1) and (((424/1.49).CCLS.) or ((424/9.34).CCLS.) or ((435/4).CCLS.) or ((435/7.21).CCLS.) or ((435/7.23).CCLS.) or ((435/960).CCLS.))	USPAT; US-PGPUB; EPO; JPO; DEFWENT	2002/09/10 16:41

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:
 sssptau182das
 LOGINID:
 PASSWORD:
 TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
 NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
 NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
 NEWS 4 Apr 09 EDB will be removed from STN
 NEWS 5 Apr 10 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
 NEWS 6 Apr 09 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
 NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
 NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
 NEWS 9 Jun 03 New e-mail delivery for search results now available
 NEWS 10 Jun 10 MEDLINE Reload
 NEWS 11 Jun 10 ECTFULL has been reloaded
 NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
 NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
 saved answer sets no longer valid
 NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
 NEWS 15 Jul 30 NETFIRST to be removed from STN
 NEWS 16 Aug 03 CANCERLIT reload
 NEWS 17 Aug 03 PHARMAMarketLetter(PHARMAML) - new on STN
 NEWS 18 Aug 03 NTIS has been reloaded and enhanced
 NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
 now available on STN
 NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
 NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
 NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
 NEWS 23 Sep 03 JAFIO has been reloaded and enhanced

NEWS EXPRESS February 1 CURRENT WINDOWS VERSION IS V6.0d,
 CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP),
 AND CURRENT DISCOVER FILE IS DATED 05 FEBRUARY 2002
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:53:53 ON 10 SEP 2002

=> file biosis
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 13:54:13 ON 10 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNS) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 4 September 2002 (20020904/ED)

=> pdx(W)1
PDX(W)1 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s pdx(W)1
 328 PDX
 2769592 1
L1 214 PDX(W)1

=> s idx(W)1
 157 IDX
 1769592 1
L2 38 IDX(W)1

=> s ipf(W)1
 665 IPF
 7 IPFS
 669 IPF
 (IPF OR IPFS)
 1769592 1
L3 64 IPF(W)1

=> s stf(W)1
 154 STF
 24 STFS
 168 STF
 (STF OR STFS)
 1769592 1
L4 45 STF(W)1

=> s pdx1
L5 81 PDX1

=> s idx1
L6 5 IDX1

=> s ipf1
L7 59 IPF1

=> s stf1
L8 13 STF1

=> s islet(W)duodenum(W)homeo?(W)protein(W)1

```

19580 ISLET
14865 ISLETS
27897 ISLET
      (ISLET OR ISLETS)
16771 DUODENUM
      40 DUODENUMS
      116 DUODENA
16849 DUODENUM
      (DUODENUM OR DUODENUMS OR DUODENA)
994369 HOMEQ?
1234078 PROTEIN
464105 PROTEINS
1423261 PROTEIN
      (PROTEIN OR PROTEINS)
2769592 1
L9      0 ISLET(W) DUODENUM(W) HOMEQ?(W) PROTEIN(W) 1

=> s insulin(W)promoter(W)factor(W) 1
196120 INSULIN
      991 INSULINS
196290 INSULIN
      (INSULIN OR INSULINS)
63569 PROMETER
      23024 PROMETERS
102945 PROMETER
      (PROMETER OR PROMETERS)
666185 FACTOR
498806 FACTORS
1051474 FACTOR
      (FACTOR OR FACTORS)
2769592 1
L10     31 INSULIN(W) PROMETER(W) FACTOR(W) 1

=> s somatostatin(W)transcrip?(W)factor(W) 1
24819 SOMATOSTATIN
      95 SOMATOSTATINS
24939 SOMATOSTATIN
      (SOMATOSTATIN OR SOMATOSTATINS)
272003 TRANSCRIP?
666185 FACTOR
498806 FACTORS
1051474 FACTOR
      (FACTOR OR FACTORS)
2769592 1
L11     9 SOMATOSTATIN(W) TRANSCRIP?(W) FACTOR(W) 1

=> s 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 110 or 111
L12     454 L1 OR L2 OR L3 OR L4 OR L5 OR L6 OR L7 OR L8 OR L9 OR L10 OR L11

=> s pancrea?
6 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s pancrea?
L13     17016 PANCREA?

=> s duct
=> s duct?
L14     63670 DUCT?

=> s divid
=> s divid? or division or propagat? or proliferat? or mitotic? or mitosis

```

111857 DIVID?
 45962 DIVISION
 9119 DIVISIONS
 52158 DIVISION
 (DIVISION OR DIVISIONS)
 34208 PROPAGAT?
 215599 PROLIFERAT?
 34186 MITOTIC?
 23295 MITOSIS
 3790 MITOSES
 26106 MITOSIS
 (MITOSIS OR MITOSES)
 L15 434631 DIVID? OR DIVISION OR PROPAGAT? OR PROLIFERAT? OR MITOTIC? OR
 MITOSIS

=> s l12 and l13 and l14 and l15
 L16 16 L12 AND L13 AND L14 AND L15

=> save temp
 ENTER L#, L# RANGE, ALL, OR (END):l16
 ENTER NAME OR (END):idx1/a
 ANSWER SET L16 HAS BEEN SAVED AS 'IDX1/A'

=> file ca		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	18.26	18.47

FILE 'CA' ENTERED AT 14:07:32 ON 10 SEP 2002
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2002 VOL 137 ISS 11
 FILE LAST UPDATED: 5 Sep 2002 (20020905/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l16
 695 PLX
 7055386 1
 157 PEX(W) 1
 117 IEX
 7055386 1
 35 IEX(W) 1
 351 CFF
 11 IPFS

356 IPF
 (IPF OR IPFS)
 7055386 1
 59 IPF(W) 1
 350 STF
 41 STFS
 375 STF
 (STF OR STFS)
 7055386 1
 46 STF(W) 1
 149 PDX1
 19 IDX1
 80 IPF1
 34 STF1
 20070 ISLET
 11986 ISLETS
 22753 ISLET
 (ISLET OR ISLETS)
 15382 DUODENUM
 48 DUODENUMS
 93 DUODENA
 15421 DUODENUM
 (DUODENUM OR DUODENUMS OR DUODENA)
 34769 HOMEQ?
 1397970 PROTEIN
 925628 PROTEINS
 1612137 PROTEIN
 (PROTEIN OR PROTEINS)
 7055386 1
 0 ISLET(W) DUODENUM(W) HOMEQ?(W) PROTEIN(W) 1
 139813 INSULIN
 5107 INSULINS
 139917 INSULIN
 (INSULIN OR INSULINS)
 121429 PROMOTER
 40101 PROMOTERS
 132090 PROMOTER
 (PROMOTER OR PROMOTERS)
 710782 FACTOR
 616573 FACTORS
 1122846 FACTOR
 (FACTOR OR FACTORS)
 7055386 1
 32 INSULIN(W) PROMOTER(W) FACTOR(W) 1
 16148 SOMATOSTATIN
 129 SOMATOSTATINS
 16154 SOMATOSTATIN
 (SOMATOSTATIN OR SOMATOSTATINS)
 267101 TRANSCRIP?
 710782 FACTOR
 616573 FACTORS
 1122846 FACTOR
 (FACTOR OR FACTORS)
 7055386 1
 8 SOMATOSTATIN(W) TRANSCRIP?(W) FACTOR(W) 1
 64227 PANCREAS
 4123 DUCT
 110007 DIVID?
 15453 DIVISION
 5029 DIVISIONS
 59424 DIVISION
 (DIVISION OR DIVISIONS)
 128410 REGULATOR
 154870 PROLIFERAT?

23240 MITOTIC?
24306 MITOSIS
1922 MITOSES
25365 MITOSIS
(MITOSIS OR MITOSES)

L17 16 L12 AND L13 AND L14 AND L15

=> duplicate rem

ENTER L# LIST OR (END):116-117

DUPLICATE PREFERENCE IS 'BIOSIS, CA'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

51.53

70.00

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 14:08:13 ON 10 SEP 2002
COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'CA' ENTERED AT 14:08:13 ON 10 SEP 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGE/TERMS" FOR DETAILS.
COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)
PROCESSING COMPLETED FOR L16
PROCESSING COMPLETED FOR L17
L19 21 DUPLICATE REM L16-L17 (11 DUPLICATES REMOVED)

=> d 118 1-21 bib ab

L18 ANSWER 1 OF 21 CA COPYRIGHT 2002 ACS
AN 136:131238 CA
TI Bile **duct** progenitor cells and methods of use
IN Pang, Kevin; Homa, Monica
PA USA
SC U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 973,938.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002012653	A1	20020131	US 1997-994539	19971219
	WO 9640872	A1	19961219	WO 1996-US9656	19960607
	W: AU, CA, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PPAI	WO 1996-US9656	W	19960607		
	US 1998-973938	A2	19980321		
	US 1995-478064	A	19950607		
AB	The present invention relates to a substantially pure population of viable bile duct progenitor cells, and methods for isolating such cells. The present invention further concerns certain therapeutic uses for such progenitor cells, and their progeny.				

L18 ANSWER 2 OF 21 CA COPYRIGHT 2002 ACS
AN 135:24733 CA
TI **Pancreatic** stem cells and their use in transplantation
IN Abraham, Elizabeth J.; Faustman, Denise; Habener, Joel L.; Vallejo, Mario; Zolowski, Hendrik
PA General Hospital Corporation, USA
SC PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI WO 2001039784 A1 20010607 WO 2000-US33031 20001206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LF, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AE, BY, FG, FK, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LJ, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2001024824 A1 20010927 US 2000-731255 20001206
US 2001046489 A1 20011129 US 2000-731261 20001206
PRAI US 1999-169032P P 19991206
US 2000-215109P P 20000628
US 2000-238880P P 20001006

AB Methods and compns. are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions in a patient using newly identified stem cells that are capable of differentiation into a variety of **pancreatic** islet cells, including insulin-producing beta cells, as well as hepatocytes. Addnl., the patient may be treated with an immunosuppressant agent. Nestin has been identified as a mol. marker for **pancreatic** stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet **ductal** cells. Methods are described whereby nestin-pos. stem cells can be isolated from **pancreatic** islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the **pancreatic** stem cells are disclosed. Methods are described whereby **pancreatic** stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogeneically, to provide replacement for lost or damaged insulin-secreting cells or other cells. For example, a 3-fold stimulation of nestin mRNA levels in the islets cultured in high glucose compared to the islets cultured in normal glucose was obsd. Similarly, injection of glucagon-like peptide 1 (GLP-1) into mice was found to increase islet mass by 2-fold in 48 h.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 3 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
1

AN 2002:280266 BIOSIS

DN PREV200200280266

TI **Pancreatic** duodenal homeobox-1, **PDX-1**, a major regulator of beta cell identity and function.

AU McKinnon, C. M.; Docherty, K. (1)

CS (1) Department of Molecular and Cell Biology, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, AB25 2ZD; k.docherty@aberndeen.ac.uk UK

SO Diabetologia, (October, 2001) Vol 44, No. 10, pp. 1203-1214 print. ISSN: 0012-186X.

DT General Review

LA English

AB **Pancreatic** duodenal homeobox -1 is a transcription factor that is expressed in beta and delta cells of the islets of Langerhans and in dispersed endocrine cells of the duodenum. It is involved in regulating the expression of a number of key beta-cell genes as well as somatostatin. It also plays a pivotal part in the development of the **pancreas** and islet cell ontogeny. Thus homozygous disruption of the gene in mice and humans results in **pancreatic** agenesis. Heterozygous mutations in the gene result in impaired glucose tolerance and symptoms of diabetes as seen in MODY4 and late-onset Type II (non-insulin-dependent) diabetes mellitus. In adults **pancreatic** duodenal homeobox-1 expression is increased in **duct** cells of the **pancreas**

that have been induced to **proliferate** and differentiate to form new islets. Defects in **pancreatic** duodenal homeobox-1 could therefore contribute to Type II diabetes by affecting compensatory mechanisms that increase the rate of beta-cell neogenesis to meet the increased insulin secretory demand. It could also be a pharmacological target for beta-cell defects in Type II diabetes, while its role as a regulator of islet stem cell activity is being exploited to produce a replenishable source of islet tissue for transplantation in Type I (insulin-dependent) diabetes mellitus.

L18 ANSWER 4 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
2

AN 2001:142229 BIOSIS

DN PREV200100142229

TI PDX:PBX complexes are required for normal **proliferation** of **pancreatic** cells during development.

AU Dutta, Sanjoy; Gannon, Maureen; Peers, Bernard; Wright, Chris; Bonner-Weir, Susan; Montminy, Marc (1)

CS (1) Clayton Laboratories for Peptide Biology, Salk Institute, 10010 North Torrey Pines Road, La Jolla, CA, 92037; montminy@salk.edu USA

SO Proceedings of the National Academy of Sciences of the United States of America January 30, 2001 Vol. 98, No. 2, pp. 1065-1070. print.
ISSN: 0027-8124.

DT Article

LA English

SL English

AB The homeobox factor **PDX-1** is a key regulator of **pancreatic** morphogenesis and glucose homeostasis; targeted disruption of the **PDX-1** gene leads to **pancreatic** agenesis in **pdx-1**(-/-) homozygotes. **Pdx-1** heterozygotes develop normally, but they display glucose intolerance in adulthood. Like certain other homeobox proteins, **PDX-1** contains a consensus FPWMK motif that promotes heterodimer formation with the ubiquitous homeodomain protein PBX. To evaluate the importance of **PDX-1:PBX** complexes in **pancreatic** morphogenesis and glucose homeostasis, we expressed either wild-type or PBX interaction defective **PDX-1** transgenes under control of the **PDX-1** promoter. Both wild-type and mutant **PDX-1** transgenes corrected glucose intolerance in **pdx-1** heterozygotes. The wild-type **PDX-1** transgene rescued the development of all **pancreatic** lineages in **pdx-1**(-/-) animals, and these mice survived to adulthood. In contrast, **pancreata** from **pdx-1**(-/-) mice expressing the mutant **PDX-1** transgene were hypoplastic, and these mice died within 3 weeks of birth from **pancreatic** insufficiency. All **pancreatic** cell types were observed in **pdx-1**(-/-) mice expressing the mutant **PDX-1** transgene; but the islets were smaller, and increased numbers of islet hormone-positive cells were noted within the **ductal** epithelium. These results indicate that **PDX-1:PBX** complexes are dispensable for glucose homeostasis and for differentiation of stem cells into **ductal**, endocrine, and acinar lineages; but they are essential for expansion of these populations during development.

L18 ANSWER 5 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
2

AN 2001:14765 BIOSIS

DN PREV200100214765

TI Multipotential nestin-positive stem cells isolated from adult **pancreatic** islets differentiate ex vivo into **pancreatic** endocrine, exocrine, and hepatic phenotypes.

AU Zurewski, Henryk; Abraham, Elizabeth J.; Gerlach, Melissa J.; Daniel, Philip B.; Moritz, Wolfgang; Muller, Beat; Vallejo, Mario; Thomas, Melissa

K.; Habener, Joel F. (1)
CS (1) Laboratory of Molecular Endocrinology, Massachusetts General Hospital,
55 Fruit St., WEL320, Boston, MA, 02114: jhabener@partners.org USA
SO Diabetes, (March, 2001) Vol. 50, No. 3, pp. 521-533. print.
ISSN: 0012-1797.

DT Article

LA English

SL English

AB The endocrine cells of the rat **pancreatic** islets of Langerhans, including insulin-producing beta-cells, turn over every 40-50 days by processes of apoptosis and the **proliferation** and differentiation of new islet cells (neo-genesis) from progenitor epithelial cells located in the **pancreatic ducts**. However, the administration to rats of islet trophic factors such as glucose or glucagon-like peptide 1 for 48 h results in a doubling of islet cell mass, suggesting that islet progenitor cells may reside within the islets themselves. Here we show that rat and human **pancreatic** islets contain a heretofore unrecognized distinct population of cells that express the neural stem cell-specific marker nestin. Nestin-positive cells within **pancreatic** islets express neither the hormones insulin, glucagon, somatostatin, or **pancreatic** polypeptide nor the markers of vascular endothelium or neurons, such as collagen IV and galanin. Focal regions of nestin-positive cells are also identified in large, small, and centrolcular **ducts** of the rat **pancreas**. Nestin-positive cells in the islets and in **pancreatic ducts** are distinct from **ductal** epithelium because they do not express the **ductal** marker cytokeratin 19 (CK19). After their isolation, these nestin-positive cells have an unusually extended **proliferative** capacity when cultured in vitro (apprx8 months), can be cloned repeatedly, and appear to be multipotential. Upon confluence, they are able to differentiate into cells that express liver and exocrine **pancreas** markers, such as alpha-fetoprotein and **pancreatic** amylase, and display a **ductal**/endocrine phenotype with expression of CK19, neural-specific cell adhesion molecule, insulin, glucagon, and the **pancreas**/duodenum specific homeodomain transcription factor, **IDX-1**. We propose that these nestin-positive islet-derived progenitor (NIP) cells are a distinct population of cells that reside within **pancreatic** islets and may participate in the neogenesis of islet endocrine cells. The NIP cells that also reside in the **pancreatic ducts** may be contributors to the established location of islet progenitor cells. The identification of NIP cells within the **pancreatic** islets themselves suggest possibilities for treatment of diabetes, whereby NIP cells isolated from **pancreas** biopsies could be expanded ex vivo and transplanted into the donor/recipient.

L18 ANSWER 6 OF 21 CA COPYRIGHT 2002 ACS

AN 133:38709 CA

TI An animal model for identifying a common stem/progenitor to liver cells and **pancreatic** cells

IN Sarvetnick, Nora; Krakowski, Michelle L.; Kritzik, Marcie R.

PA The Scripps Research Institute, USA

SO PET Int. Appl., 47 pp.

CODEN: PIXXDE

DT Patent

LA English

FAN.CN1 1

	PATENT NO	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000036091	A2	20000622	WO 1999-US29490	19991213
	WO 2000036091	A3	20001109		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BE, BY, CA, CH, CN, CR, CU, CE, DE, DK, DM, EE, ES, FI, GE, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,

MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
 SL, TJ, TM, TR, TT, TZ, UA, UG, US, UE, VN, YU, ZA, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1141247 A2 20011010 EP 1999-967280 19991213
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

US 2001013134 A1 20010809 US 2001-826779 20010405
 PRAI US 1998-212531 A2 19981216
 WO 1999-US29490 W 19991213

AB The invention provides animal models, where the ectopic expression of KGF, EGF, or both is under the control of a **pancreas**-specific promoter, e.g., the insulin promoter. The expression of KGF in the ins-KGF **pancreatic** islets of Langerhans results in enlarged islets, with substantial **proliferation** of **duct** cells within the islet mass, and the presence of albumin and alpha-fetoprotein-producing hepatocytes in the islets of the ins-KGF **pancreata**. The compns. and methods disclosed are useful for identifying and isolating **pancreatic** stem/progenitor cells, including a common stem/progenitor to liver cells and **pancreatic** cells.

L18 ANSWER 7 OF 21 CA COPYRIGHT 2002 ACS

AN 135:301720 CA

TI Human **pancreatic** stem cell and diabetes cell therapy

AU Pattou, Francois; Ferr-Conte, Julie; Gmyr, Valery; Vandewalle, Brigitte; Vantuyghem, Marie-Christine; Lecomte-Houcke, Martine; Proye, Charles; Lefebvre, Jean

CS Hospitalio-Universitaire, UFRES 1048 de Universite de Lille 2 et Service de Chirurgie Generale et Endocrinienne, Centre Hospitalier, Universitaire de Lille, Lille, F59037, Fr.

SO Bulletin de l'Academie Nationale de Medecine (Paris, France) (2000), 184(9), 1887-1901

CODEN: BANMAC; ISSN: 0001-4079

PB Academie Nationale de Medecine

DT Journal, General Review

LA French

AB A review, with refs. Cell therapy offers today important perspectives for the treatment of type 1 diabetes. The current utilization of primary human islets of Langerhans nevertheless forbids all hope of developing this treatment on a large scale. The recent description of the persistence of stem cells capable of **proliferating** and differentiating in the adult **pancreas** offers an attractive alternative for the prodn. in vitro of homologous insulin-secreting cells. We first reproduced in vitro from human islet preps. the **proliferation** of **ductal** epithelial structures and their progressive organization. Thereafter, we focused on the description of a reproducible source of human **ductal** cells by the transdifferentiation of exocrine preps. More recently we described in these exocrine derived **ductal** cells the expression the of **insulin promoter factor-1** (**IPF-1**/otherwise known as **PDX-1**), a transcription factor essential for the differentiation of **ductal** cells into endocrine cells during both development and **pancreatic** regeneration. If the **proliferation** and differentiation of these cells is confirmed, this approach could lead to the description of an abundant source of human **pancreatic** stem cells for the prodn. ex vivo of human insulin secreting cells and may even allow autologous cell therapy, in the absence of immunosuppression.

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 8 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
4

AN 2001:267534 BIOSIS

DN PREV200100267534

TI Adult human cytokeratin 19-positive cells reexpress **insulin promoter factor 1** in vitro: Further evidence for pluripotent **pancreatic** stem cells in humans.

AU Gmyr, Valery; Kerr-Conte, Julie (1); Belaich, Sandrine; Vandewalle, Brigitte; Leteurtre, Emmanuelle; Vantuyghem, Marie Christine; Lecomte-Houcke, Martine; Proye, Charles; Lefebvre, Jean; Pattou, Francois
CS (1) Laboratory of Cell Culture, University Hospital Center of Lille, 1 Place de Verdun, Lille, 59045: jkerr-conte@univ-lille2.fr France
SO Diabetes, (October, 2000) Vol. 49, No. 10, pp. 1671-1680. print.
ISSN: 0012-1797.

DT Article

LA English

SL English

AB Human **pancreatic** cells with a typical **ductal** phenotype and potential to **proliferate** can be obtained in vitro, but the differentiation capacity of these putative human **pancreatic** stem cells remains to be documented. We investigated the protein and mRNA expression of **insulin promoter factor 1 (IPF-1)** (or **pancreas/duodenal homeobox 1**), a transcription factor critical for **pancreatic** development and endocrine cell neogenesis, in human **pancreatic ductal** cells derived from cultured exocrine tissue. In vitro, exocrine cells rapidly adhered (within 12 h) and were de-/transdifferentiated to **ductal** cells after 3 days with a dramatic loss of amylase protein ($n = 4$, $92 \pm 3.3\%$, $P < 0.05$ vs. day 1) and a simultaneous increase of **ductal** cytokeratin 19 protein ($n = 4$, 3.4-fold on day 3 and 7-fold on day 9, $P < 0.05$ vs. day 1). **IPF-1** protein and mRNA levels were low to undetectable in exocrine preparations before culture. After 2 days of culture, a 3.2-fold increase in **IPF-1** protein was observed, corresponding to the characteristic 46-kDa protein in Western blots. Reverse transcriptase-polymerase chain reaction confirmed a 10.5-fold increase in **IPF-1** mRNA levels after 3 days of culture ($n = 5$, $P < 0.001$ vs. day 1). Double immunocytochemistry showed direct evidence that **IPF-1** appeared during culture in these exocrine-derived **ductal** cells (cytokeratin 7-positive) and was not merely in contaminating endocrine cells (chromogranin A-positive). In conclusion, we describe herein the first converging evidence on both the molecular and protein level that human cells with a typical **ductal** phenotype derived ex vivo from **pancreatic** exocrine tissue (obtained from healthy donors) can reexpress **IPF-1** in culture, suggesting their **pancreatic** precursor/stem cell potential.

L18 ANSWER 9 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
5

AN 2000:277198 BIOSIS

DN PREV200000277198

TI Modulation of rat **pancreatic** acinoductal transdifferentiation and expression of **PDX-1** in vitro.

AU Poorman, L.; Heremans, Y.; Heimberg, H.; Bouwens, L. (1)

CS (1) Department of Experimental Pathology, VUB, Laarbeeklaan 103, B-1090, Brussels Belgium

SO Diabetologia, (July, 2000) Vol. 43, No. 7, pp. 907-914. print.
ISSN: 0012-186X.

DT Article

LA English

SL English

AB Aims/hypothesis. In adult **pancreatic** regeneration models exocrine acini are found to transdifferentiate to **duct**-like

complexes. This has also been associated with the formation of new endocrine islet cells. We aimed to establish an in vitro model in which this transdifferentiation process is characterised and can be modulated. Methods: Purified rat **pancreatic** acini were cultured in suspension. Differentiation was analysed by immunocytochemistry, electron microscopy, western blotting and RT-PCR. Results: During culture acinar cells directly transdifferentiated without **dividing**, the cells lost their acinar phenotype and started to express cytokeratins 20 and 7 and fetal liver kinase-1 (Flk-1) receptors for vascular endothelial growth factor. Expression of the acinar **pancreatic** exocrine transcription factor (PTF-1) remained and the **pancreatic** duodenal homeobox-containing transcription factor (**PDX-1**) was induced. When transdifferentiation was completed, the cells started to express protein gene product 9.5, a panneuroendocrine marker. By combining these features, the transdifferentiated cells show similar characteristics to precursor cells during active beta-cell neogenesis. We were able to modulate the differentiation state by addition of nicotinamide or sodium butyrate, agents which are known to stimulate endocrine differentiation in other models. Conclusion/interpretation: Here, we present an in vitro system in which the cellular differentiation of putative **pancreatic** endocrine precursor cells and their **PDX 1** expression can be modulated, thereby providing a possible model for the study of beta-cell transdifferentiation.

L18 ANSWER 10 OF 21 CA COPYRIGHT 2002 ACS

AN 133:84532 CA

TI Insulintropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein **IDX-1** and increase islet size in mouse **pancreas**

AU Stoffers, Doris A.; Kieffer, Timothy J.; Hussain, Mehboob A.; Drucker, Daniel J.; Bonner-Weir, Susan; Habener, Joel F.; Egan, Josephine M.

CS Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, PA, USA

SO Diabetes (2000), 49(5), 741-748

CODEN DIAEAE; ISSN: 0012-1797

PB American Diabetes Association

DT Journal

LA English

AB Diabetes is caused by a failure of the **pancreas** to produce insulin in amts. sufficient to meet the body's needs. A hallmark of diabetes is an abs. (type 1) or relative (type 2) redn. in the mass of **pancreatic** .beta.-cells that produce insulin. Mature .beta.-cells have a life-span of .apprx.48-56 days (rat) and are replaced by the replication of preexisting .beta.-cells and by the differentiation and **proliferation** of new .beta.-cells (neogenesis) derived from the **pancreatic ducts**. The insulintropic hormone glucagon-like peptide (GLP)-1, which is produced by the intestine, enhances the **pancreatic** expression of the homeodomain transcription factor **IDX-1** that is crit. for **pancreas** development and the transcriptional regulation of the insulin gene. Concomitantly, GLP-1 administered to diabetic mice stimulates insulin secretion and effectively lowers their blood sugar levels. GLP-1 also enhances .beta.-cell neogenesis and islet size. Thus, in addn. to stimulating insulin secretion, GLP-1 stimulates the expression of the transcription factor **IDX-1** while stimulating .beta.-cell neogenesis and may thereby be an effective treatment for diabetes.

RE.CNT 45 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L18 ANSWER 11 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2001:38563 BIOSIS

DN PREV.00100038563

TI Hydrolysed casein diet protects BB rats from developing diabetes by

promoting islet neogenesis.

AU Wang, Gen-Sheng; Gruber, Heidi; Smyth, Peter; Pulido, Olga; Rosenberg, Lawrence; Duguid, William; Scott, Fraser W. (1)

CS (1) Laboratory N1, Ottawa Hospital Research Institute, Ottawa Hospital-General Campus, 501 Smyth Road, Ottawa, ON, K1H 8L6: fscott@ottawahospital.on.ca Canada

SO Journal of Autoimmunity, (Dec., 2000) Vol. 15, No. 4, pp 407-416. print. ISSN: 0896-8411.

DT Article

LA English

SL English

AB Feeding diabetes-prone BioBreeding (BBdp) rats a hydrolysed-casein (HC)-based semi-purified diet results in two-to-three-fold fewer diabetes cases compared with feeding cereal-based diets such as NIH-07 (NIH). We showed previously that young NIH-fed BBdp rats had decreased islet area at a time when classic insulinitis was minimal. Rats fed an HC diet maintained near normal islet area followed 3-4 weeks later by a deviation of the **pancreas** cytokine pattern from Th1 to Th2/Th3. This finding raised the possibility that BBdp rats were more susceptible to diet-induced changes in islet homeostasis. To investigate this possibility further, BBdp rats were fed an NIH or HC diet from days 23 to 45. Bouin's fixed sections of **pancreas** were stained with H & E or antibodies for insulin and glucagon. Cell **proliferation** nuclear antigen (PCNA) was used as a marker of cell **proliferation** and cells were stained for putative markers of islet neogenesis, cytokeratin 20 (CK20) and Bcl-2. Apoptotic bodies were recognized by morphological features and by TUNEL-positive staining. BBdp rats fed an HC diet had a significantly higher beta-cell fraction than rats fed NIH, whereas alpha-cell fraction and beta-cell size were not affected by diet or rat type. Apoptotic bodies of beta-cells were rare and unaffected by diet. The number of PCNA+ beta-cells was not affected by diet. CK20 expression was localized in the **ductular** system and at the periphery of islets in rats aged 7 and 45 days. There were more CK20+ islets in BBdp rats fed NIH than in those fed HC but the CK20 area fraction was unaffected by diet. Bcl-2 expression was scattered among **ducts** and central acinar cells. The number of extra-islet insulin+ and glucagon+ clusters (<four cells) was significantly higher in animals fed the HC diet compared with those fed NIH. Most of the insulin+ clusters were also homeobox-containing transcription factor **pancreas** duodenum homeobox gene-1 (**PDX-1**) positive. Glucagon+/**PDX-1**+ clusters were rarely found. These data are consistent with a shift in **pancreas** homeostasis that maintains islet cell mass by increased islet neogenesis, a process that was enhanced in animals fed a diabetes-retardant diet.

L18 ANSWER 12 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE

6

AN 2000:216835 BIOSIS

DN PREV200000216835

TI Diabetes and **pancreatic** tumours in transgenic mice expressing Pa

X 6.

AU Yamacka, T. (1); Yano, M.; Yamada, T.; Matsushita, T.; Moritani, M.; Ii, S.; Yoshimoto, K.; Hata, J.; Itakura, M.

CS (1) Otsuka Department of Molecular Nutrition, School of Medicine, University of Tokushima, Tokushima, 770-8503 Japan

SO Diabetologia, (March, 2000) Vol. 43, No. 3, pp. 332-339. ISSN: 0012-186X.

DT Article

LA English

SL English

AB Aims/hypothesis: Both endocrine and exocrine cells of the **pancreas** differentiate from epithelial cells of primitive **pancreatic ducts**, and four types of **pancreatic** islet cells (alpha, beta, delta, and PP cells) are derived from the common pluripotent

precursor cells. Although Pa X 6 is expressed in all islet cells, Pa X 4 is detected only in beta cells. In homozygous Pa X 4-null mice, beta cells are absent, whereas the number of alpha cells is increased. Therefore, we hypothesized that the balance of Pa X 4 and 6 is one of the determinants by which the common progenitor cells differentiate into alpha or beta cells. Methods: To change this balance, we generated transgenic mice overexpressing Pa X 6 driven by the insulin promoter or the **PDX1** promoter. Results: In both types of transgenic mice, normal development of beta cells was disturbed, resulting in apoptosis of beta cells and diabetes. In Insulin/Pa X 6-Tg mice, beta cells were specifically affected, whereas in PDX/Pa X 6-Tg mice, developmental abnormalities involved the whole **pancreas** including hypoplasia of the exocrine **pancreas**. Furthermore, PDX/Pa X 6-Tg mice experienced **proliferation** of both **ductal** epithelia and islet cells and subsequent cystic adenoma of the **pancreas**. Conclusion/interpretation: These findings suggest that Pa X 6 promotes the growth of **ductal** epithelia and endocrine progenitor cells and that the suppression of Pa X 6 is necessary for the normal development of beta cells and the exocrine **pancreas**.

L18 ANSWER 13 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 2000:59802 BIOSIS
 DN PREV200000059802
 TI Expansion of **Pdx1**-expressing **pancreatic** epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha.
 AU Song, Si Young; Gannon, Maureen; Washington, M. K.; Scoggins, Charles R.; Meszoely, Ingrid M.; Goldenring, James R.; Marino, Christopher R.; Sandgren, Eric P.; Coffey, Robert J., Jr.; Wright, Christopher V. E.; Leach, Steven D. (1)
 CS (1) Division of Surgical Oncology, T-2104 Medical Center North, Vanderbilt University Medical Center, 21st and Garland Streets, Nashville, TN USA
 SO Gastroenterology, (Dec., 1999) Vol. 117, No. 6, pp. 1416-1426.
 ISSN: 0014-5035.
 DT Article
 LA English
 SL English
 AB Background & Aims: The progenitor cells responsible for transforming growth factor (TGF)-alpha-induced **pancreatic ductal** metaplasia and neoplasia remain uncharacterized. During **pancreatic** development, differentiated cell types arise from **ductal** progenitor cells expressing the **Pdx1** homeodomain transcription factor. The aims of this study were, first, to evaluate the role of **Pdx1**-expressing stem cells in MT-TGFalpha transgenic mice, and second, to further characterize cell **proliferation** and differentiation in this model. Methods: To assess **Pdx1** gene expression in normal and metaplastic epithelium, we performed in vivo reporter gene analysis using heterozygous **Pdx1lacZ/+** and bigenic **Pdx1lacZ/+**/MT-TGFalpha mice. Results: **Pdx1lacZ/+**/MT-TGFalpha bigenics showed up-regulated **Pdx1** expression in premalignant metaplastic **ductal** epithelium. In addition to **Pdx1** gene activation, TGF-alpha-induced metaplastic epithelium demonstrated a pluripotent differentiation capacity, as evidenced by focal expression of Pax6 and initiation of islet cell neogenesis. The majority of **Pdx1**-positive epithelial cells showed no expression of insulin, similar to the pattern observed during embryonic development. Conclusions: Overexpression of TGF-alpha induces expansion of a **Pdx1**-expressing epithelium characterized by focal expression of Pax6 and initiation of islet neogenesis. These findings suggest that premalignant events induced by TGF-alpha in mouse **pancreas** may recapitulate a developmental program active during embryogenesis.

L18 ANSWER 14 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1999:324535 BIOSIS

DN PREV199900324535
 TI Activation of the **Pdx1** homeobox gene during TGFa-induced premalignant **pancreatic ductal proliferation**
 : In vivo reporter gene analysis using "double transgenic" mice.
 AU Song, Si Young (1); Gannon, Maureen (1); Meszoely, Ingrid M. (1); Scoggins, Charles R. (1); Yang, LiYing (1); Wright, Christopher V. E. (1); Coffey, Robert J. (1); Leach, S. D.
 CS (1) Vanderbilt Univ Med Ctr, Nashville, TN USA
 SO Gastroenterology, (April, 1999) Vol. 116, No. 4 PART 2, pp. A1164.
 Meeting Info.: Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association Orlando, Florida, USA May 16-19, 1999 American Gastroenterological Association
 . ISSN: 0016-5085.
 DT Conference
 LA English

L18 ANSWER 15 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
 AN 1999:293778 BIOSIS
 DN PREV199900293778

TI Sustained **proliferation** of **PDX-1**+ cells derived from human islets.
 AU Beattie, Gillian M.; Itkin Ansari, Pamela; Cirulli, Vincenzo; Leibowitz, Gil; Lopez, Ana D.; Bossie, Stuart; Mally, Martin I.; Levine, Fred; Hayek, Alberto (1)
 CS (1) Islet Research Laboratory, Department of Pediatrics, UCSD, 9894 Genesee Ave., La Jolla, CA, 92037 USA
 SO Diabetes, (May, 1999) Vol. 48, No. 5, pp. 1013-1019.
 ISSN: 0012-1797.

DT Article
 LA English
 SL English

AB Ex vivo expansion of human beta-cells is an important step toward the development of cell-based insulin delivery systems in type 1 diabetes. Here, we report that human **pancreatic** endocrine cells can be expanded through 15 cell doublings in vitro for an estimated total 30,000-fold increase in cell number. We believe that the cells resulting from these cultures are of beta-cell origin, since they uniformly express the transcription factor **PDX-1** (**STF-1**, **IDX-1**, **IPF-1**), which is initially seen only in cells positive for insulin and negative for the **ductal** cell marker cytokeratin (CK)-19. To rule out the possibility that **PDX-1** expression might be induced by the culture conditions used here, cells from isolated human **pancreatic ducts** were cultured under the same conditions as the islet cells. Cells in these cultures expressed CK-19 but not **PDX-1**. Although the expanded beta-cells continued to express **PDX-1**, insulin expression was lost over time. Whether reexpression of islet-specific genes in vitro is essential for successful cell transplantation remains to be determined.

L18 ANSWER 16 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
 7

AN 2000:95419 BIOSIS
 DN PREV200000095419

TI **PDX-1** and **Msx-2** expression in the regenerating and developing **pancreas**.

AU Kritzik, M. R.; Jones, E.; Chen, Z.; Krakowski, M.; Krah1, T.; Good, A.; Wright, C.; Fox, H.; Sarvetnick, N. (1)

CS (1) Department of Immunology, Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA, 92037 USA

SO Journal of Endocrinology, (Dec., 1999) Vol. 163, No. 3, pp. 523-530.
 ISSN: 0022-0795.

DT Article
 LA English

SL English

AB We have observed **pancreatic duct** cell **proliferation** and islet regeneration in transgenic mice whose **pancreata** produce interferon gamma (IFNg mice). We have previously demonstrated that new islet cells derive from endocrine progenitor cells in the **pancreatic ducts** of this model. The current study was initiated to define these endocrine progenitor cells further and to identify novel markers associated with **pancreatic** regeneration. Importantly, we have found that **PDX-1**, a transcription factor required for insulin gene transcription as well as for **pancreatic** development during embryogenesis, is expressed in the **duct** cells of IFNg mice. This striking observation suggests an important role for **PDX-1** in the marked regeneration observed in IFNg mice, paralleling its critical function during ontogeny. Also demonstrated was elevated expression of the homeobox-containing protein **Msx-2** in the **pancreata** of fetal mice as well as in adult IFNg mice, identifying this molecule as a novel marker associated with **pancreatic** development and regeneration as well. The identification of **PDX-1** and **Msx** in the **ducts** of the IFNg transgenic **pancreas** but not in the **ducts** of the non-transgenic **pancreas** suggests that these molecules are associated with endocrine precursor cells in the **ducts** of the IFNg transgenic mouse.

L18 ANSWER 17 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
8

AN 1999:153690 BIOSIS

DN PREV199900153690

TI The homeodomain protein **IDX-1** increases after an early burst of **proliferation** during **pancreatic** regeneration.

AU Sharma, Arun; Zangen, David H.; Reitz, Petra; Taneja, Monica; Lissauer, Matthew E.; Miller, Christopher P.; Weir, Gordon C.; Habener, Joel F.; Bonner-Weir, Susan (1)

CS (1) Joslin Diabetes Cent., One Joslin Pl., Boston, MA 02215 USA

SO Diabetes, (March, 1999) Vol. 48, No. 3, pp. 507-513.

ISSN: 0012-1797.

DT Article

LA English

AB Islet duodenal homeobox 1 (**IDX-1/IPF-1/STF-1/PDX-1**), a

homeodomain protein that transactivates the insulin promoter, has been shown by targeted gene ablation to be required for **pancreatic** development. After 90% **pancreatectomy** (Px), the adult **pancreas** regenerates in a process recapitulating embryonic development, starting with a burst of **proliferation** in the epithelium of the common **pancreatic duct**. In this model, **IDX-1** mRNA was detected by semiquantitative reverse transcription-polymerase chain reaction in total RNA from isolated common **pancreatic ducts** at levels 10% of those of isolated islets. The **IDX-1** mRNA levels were not significantly different for common **pancreatic ducts** of Px, sham Px, and unoperated rats and did not change with time after surgery. By immunoblot analysis, **IDX-1** protein was only faintly detected in these **ducts** 1 and 7 days after Px or sham Px but was easily detected at 2 and 3 days after Px. Similarly, **IDX-1** immunostaining was barely detectable in sham or unoperated **ducts** but was strong in **ducts** at 2-3 days after Px. The increase of **IDX-1** immunostaining followed that of BrdU incorporation (**proliferation**). These results indicate a posttranscriptional regulation of the **IDX-1** expression in **ducts**. In addition, islets isolated 3-7 d after Px showed higher **IDX-1** protein expression than control islets. Thus, in **pancreatic** regeneration **IDX-1** is upregulated in newly divided ductal cells

as well as in islets. The timing of enhanced expression of **IDX-1** implies that **IDX-1** is not important in the initiation of regeneration but may be involved in the differentiation of **ductal** cells to beta-cells.

L18 ANSWER 18 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 1999:289195 BIOSIS

DN PREV199900289195

TI Ontogeny of peptide growth factor and transcription factor expression during induced islet cell neogenesis in the neonatal rat **pancreas**

AU Arany, E. (1); Strutt, B.; Duvillie, B.; Hill, D. J.

CS (1) Lawson Research Institute, St Joseph's Health Centre, University of Western Ontario, London, Ontario, N6A 4V2 Canada

SO Journal of Endocrinology, (March, 1999) Vol. 160, No. SUPPL., pp. P124.

Meeting Info.: 18th Joint Meeting of the British Endocrine Societies Bournemouth, England, UK April 12-15, 1999 British Endocrine Societies . ISSN: 0022-0795.

DT Conference

LA English

L18 ANSWER 19 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
9

AN 1997:390039 BIOSIS

DN PREV199799689242

TI Demonstration of two different processes of beta-cell regeneration in a new diabetic mouse model induced by selective perfusion of alloxan.

AU Waguri, Masako (1); Yamamoto, Koji; Miyagawa, Jun-Ichiro; Tochino, Yoshihiro; Yamamori, Katsumi; Kajimoto, Yoshitaka; Nakajima, Hiromu; Watada, Hirotaka; Yoshiuchi, Issei; Itoh, Naoto; Imagawa, Akihisa; Namba, Mitsuyoshi; Kuwajima, Masamichi; Yamasaki, Yoshimitsu; Hanafusa, Toshiaki; Matsuzawa, Yuji

CS (1) Second Dep Intern. Med., Osaka Univ. Med. Sch., 2-2 Yamada-oka, Suita, Osaka 565 Japan

SO Diabetes, (1997) Vol. 46, No. 8, pp. 1281-1290.
ISSN: 0012-1797.

DT Article

LA English

AB To clarify the regeneration process of **pancreatic** beta-cells, we established a new mouse model of diabetes induced by selective perfusion of alloxan after clamping the superior mesenteric artery. In this model, diabetes could be induced by the destruction of beta-cells in alloxan-perfused segments, while beta-cells in nonperfused segments were spared. Intraperitoneal glucose tolerance tests showed glucose intolerance, which gradually ameliorated and was completely normalized in 1 year with a concomitant increase of insulin content in the **pancreas**. Histological examination showed neo-islet formation in the alloxan-perfused segment and the **proliferation** of spared beta-cells in the nonperfused segment. In the alloxan-perfused segment, despite a marked reduction of islets in size and number at an early stage, both the number of islets, including islet-like cell clusters (ICCs), and the relative islet area significantly increased at a later stage. Increased single beta-cells and ICCs were located in close contact with **duct** cell lining, suggesting that they differentiated from **duct** cells and that such extra-islet precursor cells may be important for beta-cell regeneration in beta-cell-depleted segment. In addition to beta-cells, some nonhormone cells in ICCs were positive for nuclear **insulin promoter factor 1**, which indicated that most, if not all, nonhormone cells positive for this factor were beta-cell precursors. In the nonperfused segment, the islet area increased significantly, and the highest 5-bromo-2-deoxyuridine-labeling index in beta-cells was observed at day 5, while the number of islets did not increase significantly. This indicated that the regeneration of islet endocrine cells occurs mostly through the

proliferation of preexisting intra-islet beta-cells in the nonperfused segment. In conclusion, the regeneration process of beta-cells varied by circumstance. Our mouse model is useful for studying the mechanism of regeneration, since differentiation and **proliferation** could be analyzed separately in one **pancreas**.

L18 ANSWER 20 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
10

AN 1997:202299 BIOSIS

DN PREV199799501502

TI Alpha-Cell neogenesis in an animal model of IDDM.

AU O'Reilly, Lorraine A.; Gu, Danling; Sarvetnick, Nora; Edlund, Helena; Phillips, Jenny M.; Fulford, Tony; Cooke, Anne (1)

CS (1) Dep. Pathology, Immunology Div., Univ. Cambridge, Tennis Court Road, Cambridge CB2 1QP UK

SO Diabetes, (1997) Vol. 46, No. 4, pp. 599-606.

ISSN: 0012-1797.

DT Article

LA English

AB Currently there is debate regarding the capacity of **pancreatic** islets to regenerate in adult animals. Because **pancreatic** endocrine cells are thought to arise from **duct** cells, we examined the **pancreatic ductal** epithelium of the diabetic NOD mouse for evidence of islet neogenesis. We have evidence of **duct proliferation** as well as **ductal cell** differentiation, as suggested by bromodeoxyuridine-labeling and the presence of glucagon-containing cells within these **ducts**. In addition, the **ductal** epithelia in diabetic NOD mice expressed the neuroendocrine markers neuropeptide Y and tyrosine hydroxylase. These **ducts** also expressed the homeobox gene product, insulin promoter factor 1. **Ductal cell proliferation** and expression of these markers was not observed in transgenic NOD mice (NOD-E), which do not develop clinical or histopathological symptoms of IDDM. This suggests that the observed **ductal cell proliferation** and differentiation was a direct result of beta-cell destruction and insulin insufficiency in these adult diabetic mice, which further suggests that these events are recapitulating islet ontogeny observed during embryogenesis. It is possible that comparable processes occur in the human diabetic **pancreas**.

L18 ANSWER 21 OF 21 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.DUPLICATE
11

AN 1996:216872 BIOSIS

DN PREV199698773001

TI **PDX-1** is required for **pancreatic** outgrowth and differentiation of the rostral duodenum.

AU Offield, Martin F.; Jetton, Tom L.; Labosky, Patricia A.; Ray, Michael; Stein, Roland W.; Magnuson, Mark A.; Hogan, Brigid L.; Wright, Christopher V. E. (1)

CS (1) Dep. Cell Biol., Vanderbilt Univ. Sch. Med., 1161 21st Avenue South, Nashville, TN 37232-2175 USA

SO Development (Cambridge), (1996) Vol. 122, No. 3, pp. 983-995.

ISSN: 0950-1991.

DT Article

LA English

AB It has been proposed that the Xenopus homeobox gene, XlHbox8, is involved in endodermal differentiation during **pancreatic** and duodenal development (Wright, C. V. E., Schnegelsberg, P. and De Robertis, E. M. (1996). Development 125, 787-794). To test this hypothesis directly, gene targeting was used to make two different null mutations in the mouse XlHbox8 homolog, **pdx-1**. In the first, the second **pdx-1** exon, including the homeobox, was replaced by a neomycin resistance cassette. In the second, a lacZ reporter was fused in-frame with the N terminus of **PDX-1**, replacing most of the homeodomain.

Neonatal **pdx-1**-/-mice are apancreatic, in confirmation of previous reports (Jonsson, J., Carlsson, L., Edlund, T. and Edlund, H. (1994). Nature 371, 606-609). However, the **pancreatic** buds do form in homozygous mutants, and the dorsal bud undergoes limited **proliferation** and outgrowth to form a small, irregularly branched, **ductular** tree. This outgrowth does not contain insulin or amylase-positive cells, but glucagon-expressing cells are found. The rostral duodenum shows a local absence of the normal columnar epithelia) lining, villi, and Brunner's glands, which are replaced by a GLUT2-positive cuboidal epithelium resembling the bile **duct** lining. Just distal of the abnormal epithelium, the numbers of enteroendocrine cells in the villi are greatly reduced. The **PDX-1**/beta-galactosidase fusion allele is expressed in **pancreatic** and duodenal cells in the absence of functional **PDX-1**, with expression continuing into perinatal stages with similar boundaries and expression levels. These results offer additional insight into the role of **pdx-1** in the determination and differentiation of the posterior foregut, particularly regarding the **proliferation** and differentiation of the **pancreatic** progenitors.

=> log y		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	43.33	112.33
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-2.95	-2.95

STN INTERNATIONAL LOGOFF AT 14:09:00 ON 10 SEP 2002